Novel Knowledge of Macrolide Resistance in Mycoplasma pneumoniae by Azithromycin Exposure

Tomohiro Oishi,Nemu Hattori,Daisuke Yoshioka

DOI: https://doi.org/10.3390/microorganisms12010218

IF: 4.5

2024-01-21

Microorganisms

Abstract:The rise of macrolide-resistant Mycoplasma pneumoniae (MRMP), marked by point mutations in the 23S rRNA gene, poses a growing global concern since its initial detection in 2001. The prominence of the A2063G mutation during this emergence remains unexplained. This study aimed to clarify the possibility of detecting MRMP from recent clinical macrolide-susceptible M. pneumoniae through exposure to azithromycin (AZM), which has a long half-life and was launched immediately before the first MRMP detection. Six strains isolated from Japanese children in 2019 and reference strain (FH), all belonging to the recent dominant P1 genotype, two, or two subtype, were cultivated in a medium containing slightly higher concentrations than the originated minimum inhibitory concentration (MIC) of AZM and underwent sequencing if they grew. Four out of the seven strains grew after exposure to AZM, and C2617G and C2617A were detected, with no mutation in two strains. After another cultivation and sequencing, two of four strains grew, one was changed from C2617G to A2063G, and the other remained C2617A. The MIC of AZM in A2063G strains was 128 mg/mL; for C2617A, it was 0.0156 mg/mL. This is the first study to detect the strains with A2063G mutation from recent macrolide-susceptible M. pneumoniae using AZM exposure.

microbiology

What problem does this paper attempt to address?

This paper aims to explore the possibility of detecting Macrolide - Resistant Mycoplasma pneumoniae (MRMP) from recently clinically isolated Macrolide - Sensitive Mycoplasma pneumoniae through Azithromycin (AZM) exposure. Specifically, the study focused on whether Mycoplasma pneumoniae could develop resistant mutations, especially the A2063G mutation which is associated with a high level of resistance, in an Azithromycin - containing medium with a slightly higher original Minimum Inhibitory Concentration (MIC).

The research background indicates that since MRMP was first detected in Japan in 2001, its incidence has gradually increased worldwide, especially in Asia. The appearance of the A2063G mutation in these resistant strains is particularly prominent, but the reason is still unclear. Considering that Azithromycin was launched on the market in 2000 and has a long half - life, the researchers speculated that the use of Azithromycin might be related to the first detection of MRMP. Therefore, in this study, six strains of Macrolide - Sensitive Mycoplasma pneumoniae isolated from Japanese children in 2019 and one standard strain (FH) were selected for experimental research to verify this hypothesis.

The main findings of the study include:
- Four strains grew after the initial Azithromycin exposure, and C2617G and C2617A mutations were detected in two of these strains.
- After the second exposure to a higher concentration of Azithromycin, two strains continued to grow. In one of these strains, the C2617G mutation was transformed into an A2063G mutation, while the other strain maintained the C2617A mutation.
- The MIC value of the A2063G - mutated strain against Azithromycin increased significantly to 128 mg/mL, while the MIC value of the C2617A - mutated strain was 0.0156 mg/mL.

These results indicate that even in recently isolated Macrolide - Sensitive Mycoplasma pneumoniae, resistant mutations, especially the A2063G mutation, can be induced by low - concentration exposure to Azithromycin. This suggests that Macrolide - class antibiotics should be used with caution in clinical practice to prevent a further increase in the incidence of MRMP.